Department of Obstetrics and Gynecology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 7th Floor, Renji Building, No. 26 Shengli Street, Jiang'an District, Wuhan, 430000, China.
Ir J Med Sci. 2022 Apr;191(2):665-670. doi: 10.1007/s11845-021-02510-9. Epub 2021 Apr 2.
Cervical cancer is one of the most common and fatal malignancies among females, and biomarkers are essential for assisting in its management. Kinesin family member 2A (KIF2A) has been exhibited to be a potential maker in various cancers; however, its role in cervical cancer has yet to be reported. Therefore, we aimed to assess the expression of KIF2A and its correlation with clinicopathological characteristics as well as survival profile in cervical cancer patients.
A hundred and thirty-five cervical cancer patients who underwent simple trachelectomy or radical hysterectomy were retrospectively analyzed. Tumor tissues and paired adjacent tissues were acquired, in which KIF2A mRNA and protein expressions were determined by reverse transcription quantitative polymerase chain reaction and immunohistochemistry assay, respectively. Disease-free survival (DFS) and overall survival (OS) were documented with a median follow-up duration of 28.0 months.
KIF2A protein (P < 0.001) and mRNA (P < 0.001) expressions were both upregulated in tumor tissues compared to paired adjacent tissues in cervical cancer patients. In addition, tumor tissue KIF2A protein and mRNA expressions were positively associated with lymph node metastasis (P = 0.025 and P = 0.010, respectively) and FIGO stage (P = 0.022 and P = 0.015, respectively) in cervical cancer patients. Moreover, patients with tumor tissue KIF2A high expression (mRNA and protein) displayed worse DFS (P = 0.010 and P = 0.046, respectively) and OS (P = 0.042 and P = 0.030, respectively) compared to patients with tumor tissue KIF2A low expression (mRNA and protein).
Tumor tissue KIF2A expression could serve as a biomarker enhancing the disease surveillance and prognostication in cervical cancer management.
宫颈癌是女性中最常见和最致命的恶性肿瘤之一，生物标志物对于协助其管理至关重要。驱动蛋白家族成员 2A（KIF2A）已被证明是多种癌症中的一种潜在标志物；然而，其在宫颈癌中的作用尚未被报道。因此，我们旨在评估 KIF2A 的表达及其与宫颈癌患者临床病理特征和生存状况的相关性。
回顾性分析了 135 例接受单纯子宫颈管切除术或根治性子宫切除术的宫颈癌患者。获取肿瘤组织和配对的相邻组织，通过逆转录定量聚合酶链反应和免疫组织化学检测分别测定 KIF2A mRNA 和蛋白的表达。中位随访 28.0 个月后记录无病生存（DFS）和总生存（OS）。
与宫颈癌患者配对的相邻组织相比，肿瘤组织中 KIF2A 蛋白（P<0.001）和 mRNA（P<0.001）表达均上调。此外，肿瘤组织 KIF2A 蛋白和 mRNA 表达与宫颈癌患者的淋巴结转移（P=0.025 和 P=0.010）和 FIGO 分期（P=0.022 和 P=0.015）呈正相关。此外，肿瘤组织 KIF2A 高表达（mRNA 和蛋白）的患者与肿瘤组织 KIF2A 低表达（mRNA 和蛋白）的患者相比，DFS（P=0.010 和 P=0.046）和 OS（P=0.042 和 P=0.030）更差。
肿瘤组织 KIF2A 表达可作为一种生物标志物，增强宫颈癌管理中的疾病监测和预后判断。
